Related Experiment Video
Updated: Jun 7, 2026

08:29
Reinstatement of Drug-seeking in Mice Using the Conditioned Place Preference Paradigm
Published on: June 7, 2018
Oral methylphenidate establishes a conditioned place preference in rats
Thomas E Wooters1, Matthew T Walton, Michael T Bardo
1Department of Psychology, University of Kentucky, Lexington, KY 40536-0509, USA.
Neuroscience Letters
|October 27, 2010
Summary
Oral methylphenidate shows abuse potential in rats, but requires higher doses than intraperitoneal administration. Conditioning requires ascending drug levels for rewarding effects, suggesting lower abuse liability for oral methylphenidate.
Area of Science:
- Neuroscience
- Pharmacology
- Behavioral Science
Background:
- Illicit methylphenidate abuse is a growing concern.
- While intranasal abuse is common, oral (per os; p.o.) methylphenidate also presents abuse potential.
Purpose of the Study:
- To compare the abuse potential of oral (p.o.) versus intraperitoneal (i.p.) methylphenidate in a rat model.
- To investigate the effect of administration timing on methylphenidate's rewarding effects.
Main Methods:
- Rats received p.o. or i.p. methylphenidate (3 or 10 mg/kg) or saline immediately or 30 minutes before conditioning trials.
- Conditioned place preference (CPP) was used to assess the rewarding effects of methylphenidate.
- Preference was measured in a drug-free session after repeated pairings of the drug with a specific compartment.
Main Results:
- Both 3 and 10 mg/kg i.p. methylphenidate produced significant CPP when administered immediately before conditioning.
- Only 10 mg/kg p.o. methylphenidate produced significant CPP under immediate preconditioning.
- No CPP was observed for any dose of i.p. or p.o. methylphenidate when administered 30 minutes prior to conditioning.
Conclusions:
- Oral methylphenidate demonstrates rewarding effects, but at higher doses than i.p. administration.
- Conditioning appears to require ascending, not descending, drug levels, potentially explaining the reduced abuse liability of oral methylphenidate.
- Findings align with clinical observations of lower abuse potential for orally administered methylphenidate compared to other routes.

